Abpro Corp. operates as a biotechnology company which develops antibody therapeutics for severe and life threatening diseases. The company is headquartered in Woburn, Massachusetts. The Company’s Abpro’s DiversImmune platform helps to generate monoclonal antibodies. The Diversimmune platform combines the nano-immunology, next-generation sequencing, engineering and bioinformatics to create monoclonal antibodies against traditionally difficult targets. The Company’s therapies to treat cancer, eye, autoimmune, infectious diseases and other areas.